secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2025-06-13T23:59:59+00:00
Accession:  0000950170-25-086170
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Therapeutics appoints new director from Baker Bros.; shareholders approve increase in authorized shares
--------------------------------------------------------------------------------

- Appointed Paul Scherer, M.D. (Baker Bros. Advisors) as Class III director; granted options for 76,000 shares vesting over one year.
- Stockholders elected Martin Babler and Victor Sandor as Class II directors for three-year terms at 2025 annual meeting.
- Ratified Ernst & Young as independent auditor for fiscal year 2025 with 32,364,505 votes for, 132,459 against.
- Approved amendment increasing authorized non-voting common stock from 12,850,259 to 112,850,259 shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000095017025086170/0000950170-25-086170-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000095017025086170/prld-20250611.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-086170

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer